Client update: Cambrooke Therapeutics

Cambrooke Therapeutics Inc, the Private Equity-backed, Massachusetts-based therapeutic nutrition company and global provider of medical nutrition products to sick children with rare inborn errors of metabolism has successfully registered its products for sale in the UK allowing for further expansion into the EU.
This milestone was enabled by the 2016 Series C equity financing round led by leading EU-based Life Science Venture Capital Firm Seventure Partners (Paris, France) whom Ruffena Capital introduced.